| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $7,003,761 | 1 | 13 |
Sells | $644,575 | 7 | 87 |
| Cormorant Asset Management, LP | 10 percent owner | 1 | $7M | 0 | $0 | $7M |
| Altmeyer Anne | director | 0 | $0 | 1 | $10,096 | $-10,096 |
| Jenkins John Kenneth | director | 0 | $0 | 1 | $20,465 | $-20,465 |
| Smethurst Dominic | Chief Medical Officer | 0 | $0 | 1 | $43,330 | $-43,330 |
| Moran Sean F. | Chief Financial Officer | 0 | $0 | 2 | $106,926 | $-106,926 |
| Cohen Yuval | Chief Executive Officer | 0 | $0 | 2 | $463,758 | $-463,758 |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Over the last 12 months, insiders at Corbus Pharmaceuticals Holdings, Inc. have bought $7M and sold $644,575 worth of Corbus Pharmaceuticals Holdings, Inc. stock.
On average, over the past 5 years, insiders at Corbus Pharmaceuticals Holdings, Inc. have bought $10.74M and sold $777,490 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cormorant Asset Management, LP (10 percent owner) — $7M.
The last purchase of 350,000 shares for transaction amount of $7M was made by Cormorant Asset Management, LP (10 percent owner) on 2024‑09‑20.
| 2025-05-30 | Sale | Altmeyer Anne | director | 1,392 0.0111% | $7.25 | $10,096 | +16.59% | |
| 2025-05-30 | Sale | Jenkins John Kenneth | director | 2,783 0.0225% | $7.35 | $20,465 | +16.59% | |
| 2025-03-06 | Sale | Smethurst Dominic | Chief Medical Officer | 6,393 0.051% | $6.78 | $43,330 | -0.82% | |
| 2025-02-14 | Sale | Cohen Yuval | Chief Executive Officer | 7,134 0.0541% | $8.76 | $62,465 | -17.39% | |
| 2025-02-14 | Sale | Moran Sean F. | Chief Financial Officer | 2,792 0.0212% | $8.76 | $24,446 | -17.39% | |
| 2024-09-20 | Cormorant Asset Management, LP | 10 percent owner | 350,000 3.227% | $20.01 | $7M | -50.13% | ||
| 2024-06-18 | Sale | Cohen Yuval | Chief Executive Officer | 9,501 0.1849% | $42.24 | $401,294 | -67.39% | |
| 2024-06-18 | Sale | Moran Sean F. | Chief Financial Officer | 1,958 0.038% | $42.12 | $82,479 | -67.39% | |
| 2024-06-17 | Sale | Cohen Yuval | Chief Executive Officer | 1,770 0.0375% | $46.02 | $81,456 | -66.78% | |
| 2024-06-17 | Sale | Moran Sean F. | Chief Financial Officer | 6,730 0.145% | $46.77 | $314,789 | -66.78% | |
| 2024-06-14 | Sale | Cohen Yuval | Chief Executive Officer | 12,487 0.2886% | $50.17 | $626,425 | -69.90% | |
| 2024-06-14 | Sale | Moran Sean F. | Chief Financial Officer | 7,788 0.179% | $49.87 | $388,417 | -69.90% | |
| 2024-03-08 | Cormorant Asset Management, LP | 10 percent owner | 300,000 6.1345% | $44.38 | $13.31M | -17.56% | ||
| 2024-03-07 | Cormorant Asset Management, LP | 10 percent owner | 250,000 4.6136% | $40.05 | $10.01M | -7.99% | ||
| 2024-02-02 | Cormorant Asset Management, LP | 10 percent owner | 750,000 6.5656% | $19.00 | $14.25M | +39.41% | ||
| 2024-01-26 | Cormorant Asset Management, LP | 10 percent owner | 282,632 4.1983% | $32.24 | $9.11M | +26.31% | ||
| 2022-08-10 | Moran Sean F. | Chief Financial Officer | 20,000 0.0024% | $0.26 | $5,198 | -23.53% | ||
| 2022-08-10 | Cohen Yuval | Chief Executive Officer | 3,800 0.0005% | $0.26 | $1,003 | -23.53% | ||
| 2022-08-10 | Millian Craig Stuart | Chief Operating Officer | 5,000 0.0006% | $0.25 | $1,273 | -23.53% | ||
| 2022-05-16 | Moran Sean F. | Chief Financial Officer | 12,000 0.0017% | $0.30 | $3,600 | -34.56% |
| Cormorant Asset Management, LP | 10 percent owner | 2375000 19.4087% | $19.74M | 5 | 0 | +10.04% |
| Cohen Yuval | Chief Executive Officer | 138187 1.1293% | $1.15M | 25 | 4 | +10.48% |
| Moran Sean F. | Chief Financial Officer | 73313 0.5991% | $609,231.03 | 45 | 7 | +30.87% |
| Smethurst Dominic | Chief Medical Officer | 70807 0.5786% | $588,406.17 | 0 | 1 | |
| Altmeyer Anne | director | 1391 0.0114% | $11,559.21 | 0 | 1 | |
| Jenkins John Kenneth | director | 33 0.0003% | $274.23 | 1 | 1 | <0.0001% |
| Burstein Sumner | 10 percent owner | 3594846 29.3773% | $29.87M | 0 | 2 | |
| Tepper Mark | President and CSO | 2101000 17.1695% | $17.46M | 1 | 0 | |
| White Barbara | Chief Medical Officer | 206217 1.6852% | $1.71M | 27 | 0 | +9.31% |
| CATLIN AVERY W | director | 47000 0.3841% | $390,570.00 | 5 | 0 | <0.0001% |
| Discordia Robert Paul | Chief Operating Officer | 35490 0.29% | $294,921.90 | 3 | 0 | <0.0001% |
| Millian Craig Stuart | Chief Operating Officer | 27000 0.2206% | $224,370.00 | 8 | 0 | <0.0001% |
| HOLMER ALAN F | director | 22500 0.1839% | $186,975.00 | 3 | 0 | <0.0001% |
| GUPTA RENU | director | 15000 0.1226% | $124,650.00 | 3 | 0 | <0.0001% |
| Panayiotopoulos Paris | director | 14285 0.1167% | $118,708.35 | 1 | 0 | <0.0001% |
| Hochman David P | director | 7000 0.0572% | $58,170.00 | 14 | 0 | +5.91% |
$5,082,542 | 144 | 5.47% | $114.35M | |
$30,470,407 | 140 | 20.39% | $100M | |
Corbus Pharmaceuticals Holdings, Inc. (CRBP) | $49,091,668 | 110 | 13.11% | $101.69M |
$679,720 | 45 | -16.13% | $91.52M | |
$53,912,175 | 35 | -8.02% | $91.52M | |
$18,752,549 | 33 | -28.39% | $99.68M | |
$6,915,275 | 21 | -32.61% | $114.97M | |
$111,692,551 | 18 | 13.51% | $94.1M | |
$4,701,608 | 14 | -4.34% | $111.45M | |
$2,788,839 | 12 | 6.73% | $106.82M | |
$145,194 | 11 | -27.37% | $103.75M | |
$135,589,307 | 10 | 32.46% | $99.29M | |
$13,919,584 | 9 | -30.43% | $91.96M | |
$272,982 | 6 | -28.53% | $108.91M | |
$556,839 | 5 | 13.42% | $102.25M | |
$52,950 | 3 | 0.77% | $114.55M | |
$30,149,552 | 3 | -66.74% | $94.27M | |
$3,620 | 1 | 94.16% | $92.15M | |
$1,250 | 1 | 278.21% | $110.19M |
| Increased Positions | 41 | +31.54% | 2M | +15.73% |
| Decreased Positions | 53 | -40.77% | 2M | -21.1% |
| New Positions | 18 | New | 963,973 | New |
| Sold Out Positions | 28 | Sold Out | 2M | Sold Out |
| Total Postitions | 118 | -9.23% | 11M | -5.37% |
| Cormorant Asset Management, Lp | $18,501.00 | 19.79% | 2.38M | 0 | 0% | 2024-12-31 |
| Orbimed Advisors Llc | $9,132.00 | 9.77% | 1.17M | +259,735 | +28.46% | 2024-12-31 |
| Octagon Capital Advisors Lp | $8,686.00 | 9.29% | 1.11M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $6,591.00 | 7.05% | 846,062 | -27,312 | -3.13% | 2025-03-31 |
| Vanguard Group Inc | $5,135.00 | 5.49% | 659,202 | +13,552 | +2.1% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $4,120.00 | 4.41% | 528,937 | 0 | 0% | 2024-12-31 |
| Millennium Management Llc | $3,012.00 | 3.22% | 386,653 | +283,902 | +276.3% | 2024-12-31 |
| Altium Capital Management Llc | $2,999.00 | 3.21% | 385,000 | +190,000 | +97.44% | 2024-12-31 |
| Prosight Management, Lp | $2,103.00 | 2.25% | 270,000 | +140,000 | +107.69% | 2024-12-31 |
| Geode Capital Management, Llc | $2,053.00 | 2.2% | 263,532 | +13,773 | +5.51% | 2024-12-31 |